

Ref: MHL/Sec&Legal/2026-27/01

April 03, 2026

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Fair Disclosure of Unpublished Price Sensitive Information & Policy for Legitimate Purpose in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended March 31, 2026.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended March 31, 2026. A detailed information update will follow once the Board of Directors approves the financial results for Q4FY26.

The Company continued its strong momentum in business performance with consolidated revenues growing by **~23% on a year-on-year basis**. This performance was largely fueled by continued traction in the TruHealth wellness segment and specialized testing segment. Additionally, the Company recorded robust growth across both its B2B and B2C channels, supported by a balanced combination of increased volumes and product mix improvements.

Key highlights of Q4FY26 (MHL Group):

1. Revenue grew by **~23% on a Y-o-Y** basis including revenues from Core Diagnostics, Scientific Pathology (Scientific), Dr. Ahuja's Pathology & Imaging Center (DAPIC) and Dr. RS Patil's Ambika Pathology Laboratory (Ambika).
2. B2C revenue grew by ~19% and B2B revenue by ~30% on Y-o-Y basis, driven by strong specialty growth and a higher B2B contribution in Core Diagnostics; additionally, TruHealth Wellness and Specialty segments recorded growth of ~25% and ~29%, respectively on Y-o-Y basis in Q4 FY26.
3. Acquisitions completed last year are progressing well, with integration efforts and synergy benefits now translating into positive outcomes. Margin in Core Diagnostics is improving, with Q4FY26 in the high single-digit range. DAPIC, Scientific, and Ambika continue to deliver higher margin than the Company's average.

Key highlights of Q4FY26 (MHL Organic*):

1. Revenue grew by **~14.5% Y-o-Y**, largely on account of increased patient and test volume, and product mix.
2. EBITDA margins for the quarter improved on a Y-o-Y basis, driven by operating leverage and efficiency gains.

**MHL Organic – Excludes recent acquisitions of Core Diagnostics, DAPIC, Scientific and Ambika*



The quarterly business update is on a consolidated basis. The financial results of Q4FY26 are subject to Audit.

Thanking you,
Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh C Kulkarni
Head – Legal & Secretarial

